Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy.
about
Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancerManagement of pancreatic cancer in the elderlyPrognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma.Immune checkpoint therapy for pancreatic cancerComplex role for the immune system in initiation and progression of pancreatic cancer.Tumor-induced myeloid dysfunction and its implications for cancer immunotherapyMurine pancreatic adenocarcinoma reduces Ikaros expression and disrupts T cell homeostasisCharacterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells.Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapyClinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma.Novel pancreatic cancer vaccines could unleash the army within.PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.Anti-tumor properties of the cGMP/protein kinase G inhibitor DT3 in pancreatic adenocarcinoma.The novel mitochondria-targeted antioxidant SkQ1 modulates angiogenesis and inflammatory micromilieu in a murine orthotopic model of pancreatic cancer.Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy.Interferon-α Up-Regulates the Expression of PD-L1 Molecules on Immune Cells Through STAT3 and p38 SignalingCancer Immunity and Immune Evasion Mechanisms
P2860
Q26749451-A4497507-528F-4495-8D26-1C5FD73DA810Q26774639-8A137F69-E851-463F-9AA7-B5AF79006836Q27332109-64B75C05-2843-428E-AC6D-E5EF7B85902FQ28078390-B67166CA-CB14-42D4-8783-0FEBFE7EA6C5Q34093784-9D7D9591-C284-4ADF-A640-F8A09F8E618CQ34810257-4042FE60-1C87-4BB4-91A3-6DDE53839AEAQ35023580-3A012B50-D38B-4D1D-9AB4-97C2955D7588Q35799021-5A87099A-5120-4E59-99DC-8E9E8CF3CACFQ35886496-6EBE836B-4F59-48AC-B598-3E969B8ACAB0Q36252792-3A171C25-2C6C-4E12-BE77-9EE4CB3F3CE0Q37684031-DA1C519C-6D12-4FBC-92A6-95C0C2635055Q38222470-9AAEF32C-A3D0-459F-A2BB-44C3C5735B82Q38642853-AA52F912-3098-4B70-9BB4-4799DD7C113CQ38860705-C4B3506F-B5A3-48AD-B16E-6543776463E8Q46590141-BC66FF82-1CE4-45D3-A25F-007AE56BF18FQ55715408-1E40B577-2023-4726-8EF8-0A8BFEE88869Q57821146-3687ACD3-F2E9-4F2B-A0DA-58A2B4AE77AAQ58122720-146923E3-E7CE-414A-8F28-0ED7B681FB1B
P2860
Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy.
@en
type
label
Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy.
@en
prefLabel
Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy.
@en
P2093
P2860
P1476
Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy
@en
P2093
Alexandr V Bazhin
Jens Werner
Svetlana Karakhanova
Viktor Umansky
P2860
P2888
P356
10.1007/S00262-013-1485-8
P577
2013-10-16T00:00:00Z
P6179
1033418403